RU2705244C2 - Композиции и способы лечения рака мозга - Google Patents

Композиции и способы лечения рака мозга Download PDF

Info

Publication number
RU2705244C2
RU2705244C2 RU2015128078A RU2015128078A RU2705244C2 RU 2705244 C2 RU2705244 C2 RU 2705244C2 RU 2015128078 A RU2015128078 A RU 2015128078A RU 2015128078 A RU2015128078 A RU 2015128078A RU 2705244 C2 RU2705244 C2 RU 2705244C2
Authority
RU
Russia
Prior art keywords
sequence
isolated
protein
seq
virus
Prior art date
Application number
RU2015128078A
Other languages
English (en)
Russian (ru)
Other versions
RU2015128078A (ru
RU2015128078A3 (enExample
Inventor
Дэвид ШТОЙДЛЬ
Джон Камерон БЕЛЛ
Original Assignee
Тёрнстоун Лимитед Партнершип
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тёрнстоун Лимитед Партнершип filed Critical Тёрнстоун Лимитед Партнершип
Publication of RU2015128078A publication Critical patent/RU2015128078A/ru
Publication of RU2015128078A3 publication Critical patent/RU2015128078A3/ru
Application granted granted Critical
Publication of RU2705244C2 publication Critical patent/RU2705244C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20233—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
RU2015128078A 2012-12-12 2012-12-12 Композиции и способы лечения рака мозга RU2705244C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2012/050893 WO2014089668A1 (en) 2012-12-12 2012-12-12 Compositions and methods for the treatment of brain cancers

Publications (3)

Publication Number Publication Date
RU2015128078A RU2015128078A (ru) 2019-03-27
RU2015128078A3 RU2015128078A3 (enExample) 2019-03-27
RU2705244C2 true RU2705244C2 (ru) 2019-11-06

Family

ID=50933623

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015128078A RU2705244C2 (ru) 2012-12-12 2012-12-12 Композиции и способы лечения рака мозга

Country Status (11)

Country Link
US (1) US20150307559A1 (enExample)
EP (1) EP2931880B1 (enExample)
JP (1) JP6162818B2 (enExample)
CN (1) CN105008524A (enExample)
AU (1) AU2012396787B9 (enExample)
BR (1) BR112015013669A2 (enExample)
CA (1) CA2894618A1 (enExample)
IL (1) IL239374B (enExample)
MX (1) MX366493B (enExample)
RU (1) RU2705244C2 (enExample)
WO (1) WO2014089668A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011070440A2 (en) 2009-12-10 2011-06-16 Ottawa Hospital Research Institute Oncolytic rhabdovirus
EP2718427B1 (en) 2011-06-08 2017-01-11 Children's Hospital of Eastern Ontario Research Institute Inc. Compositions for glioblastoma treatment
RU2019107976A (ru) 2013-02-21 2019-08-23 Тёрнстоун Лимитед Партнершип Композиция вакцины
US12351812B2 (en) * 2017-05-19 2025-07-08 Georgia State University Research Foundation, Inc. Recombinant oncolytic virus
PT3684786T (pt) 2017-09-22 2024-10-30 Centre Nat Rech Scient Glicoproteína mutante do vírus da estomatite vesicular
DE102018215551A1 (de) 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
CN112442114A (zh) * 2019-08-29 2021-03-05 渥太华Hdl药物研发公司 一种多肽及其应用
US20240299540A1 (en) 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
IL327310A (en) 2023-09-25 2026-05-01 Kelonia Therapeutics Inc Cancer treatment vehicles
WO2026051968A1 (zh) * 2024-09-04 2026-03-12 深圳易慕峰生物科技股份有限公司 一种新型病毒颗粒及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2301260C2 (ru) * 2000-09-22 2007-06-20 Вирэкссис Корпорейшн Вирусные векторы с зависимой от условий репликацией и их применение
CA2739963A1 (en) * 2008-10-08 2010-04-15 Tsanan Heimann Lcmv-gp-vsv pseudotyped vectors and tumor infiltrating virus-producing cells for the therapy of tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2301260C2 (ru) * 2000-09-22 2007-06-20 Вирэкссис Корпорейшн Вирусные векторы с зависимой от условий репликацией и их применение
CA2739963A1 (en) * 2008-10-08 2010-04-15 Tsanan Heimann Lcmv-gp-vsv pseudotyped vectors and tumor infiltrating virus-producing cells for the therapy of tumors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALEXANDER MUIK et al., Pseudotyping Vesicular Stomatitis Virus with Lymphocytic Choriomeningitis Virus Glycoproteins Enhances Infectivity for Glioma Cells and Minimizes Neurotropism, JOURNAL OF VIROLOGY, June 2011, Vol. 85, No. 11, pp.5679-5684. *
GUIDO WOLLMANN et al., Oncolytic Virus Therapy of Glioblastoma Multiforme - Concepts;and Candidates, Cancer J. 2012, Vol.18, No.1, pp. 69-81. *
GUIDO WOLLMANN et al., Oncolytic Virus Therapy of Glioblastoma Multiforme - Concepts;and Candidates, Cancer J. 2012, Vol.18, No.1, pp. 69-81. ALEXANDER MUIK et al., Pseudotyping Vesicular Stomatitis Virus with Lymphocytic Choriomeningitis Virus Glycoproteins Enhances Infectivity for Glioma Cells and Minimizes Neurotropism, JOURNAL OF VIROLOGY, June 2011, Vol. 85, No. 11, pp.5679-5684. WINFRIED R. BEYER et al., Oncoretrovirus and Lentivirus Vectors Pseudotyped with Lymphocytic Choriomeningitis Virus Glycoprotein: Generation, Concentration, and Broad Host Range, JOURNAL OF VIROLOGY Feb. 2002, Vol. 76, No. 3, pp. 1488-1495. JAN BRUN et al., Identification of Genetically Modified Maraba Virus as an Oncolytic Rhabdovirus, Molecular Therapy Aug. 2010, Vol. 18, No.8, pp.1440-1449. *
JAN BRUN et al., Identification of Genetically Modified Maraba Virus as an Oncolytic Rhabdovirus, Molecular Therapy Aug. 2010, Vol. 18, No.8, pp.1440-1449. *
Maraba virus from Brazil, complete genome, GenBank: *
Maraba virus from Brazil, complete genome, GenBank: HQ6600766, 22.06.2011. *
WINFRIED R. BEYER et al., Oncoretrovirus and Lentivirus Vectors Pseudotyped with Lymphocytic Choriomeningitis Virus Glycoprotein: Generation, Concentration, and Broad Host Range, JOURNAL OF VIROLOGY Feb. 2002, Vol. 76, No. 3, pp. 1488-1495. *

Also Published As

Publication number Publication date
RU2015128078A (ru) 2019-03-27
CA2894618A1 (en) 2014-06-19
MX2015007093A (es) 2016-01-12
AU2012396787B2 (en) 2019-09-19
JP6162818B2 (ja) 2017-07-12
EP2931880A4 (en) 2016-05-18
JP2016501528A (ja) 2016-01-21
IL239374B (en) 2021-03-25
CN105008524A (zh) 2015-10-28
EP2931880B1 (en) 2019-03-20
BR112015013669A2 (pt) 2017-11-14
EP2931880A1 (en) 2015-10-21
AU2012396787B9 (en) 2019-10-03
WO2014089668A1 (en) 2014-06-19
US20150307559A1 (en) 2015-10-29
RU2015128078A3 (enExample) 2019-03-27
AU2012396787A1 (en) 2015-07-02
IL239374A0 (en) 2015-07-30
MX366493B (es) 2019-07-10

Similar Documents

Publication Publication Date Title
EP2931880B1 (en) Compositions and methods for the treatment of brain cancers
JP7340471B6 (ja) ウイルスベクター産生系
Lundstrom Viral vectors in gene therapy: where do we stand in 2023?
JP2001515348A (ja) 骨髄における異種性遺伝子の生体内デリバリーと発現のための方法
AU2022235209A1 (en) Minimal nephrin promoter
US20170051307A1 (en) Evolution of high-titer virus-like vesicles for vaccine applications
CN117580941A (zh) 多重CRISPR/Cas9介导的靶基因激活系统
CN113462723A (zh) 表达CAR和shRNA的逆转录病毒载体及其应用
CN101586120A (zh) 狂犬病病毒Flury-LEP疫苗株反向遗传操作系统及LEP绿色荧光蛋白重组病毒载体
KR20230123925A (ko) Neurod1 및 dlx2 벡터
CN114213505B (zh) 一种适用于特异感染u87-mg细胞的腺相关病毒突变体
US20230293668A1 (en) Compositions and methods for glioblastoma treatment
WO2015154197A1 (en) Compositions and methods for glioblastoma treatment
EP2558113B1 (en) Serca2 therapeutic compositions and methods of use
CN103160501B (zh) 基因表达盒及其构建方法和应用
CN114195859A (zh) 一种适用于特异感染u251细胞的腺相关病毒突变体
CN118406684A (zh) 一种shRNA腺相关病毒载体及其构建方法和应用
CN113846068A (zh) 融合基因ril-7重组牛痘病毒及其在制备抗肿瘤药物中的应用
CN114984189A (zh) 一种白细胞介素16蛋白的新用途
CN116761812A (zh) Neurod1和dlx2载体
CN119280376A (zh) Aw112010 orf编码蛋白在制备抗菌药物中的应用
CN106177993A (zh) 传染性法氏囊病病毒dna疫苗及其构建方法